文献速递肝病

利福昔明治疗与肝性脑病患者肝硬化并发症风险降低及总生存期延长相关

Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
PubMed 文献 · Aliment Pharmacol Ther · 2017-08-24

回顾性研究纳入1042例肝性脑病患者,分为非肝细胞癌队列421例和肝细胞癌队列621例。非肝细胞癌队列中利福昔明联合乳果糖组145例与单用乳果糖组276例相比,死亡风险显著降低(aHR 0.697,P=0.024),复发性肝性脑病、自发性细菌性腹膜炎和食管胃底静脉曲张出血风险也显著降低,但肝肾综合征风险无显著差异。肝细胞癌队列中利福昔明与死亡风险无关(aHR 1.177,P=0.121)。

要点

  • 非肝细胞癌肝性脑病患者中,利福昔明联合乳果糖与死亡风险降低显著相关(aHR 0.697,P=0.024)。
  • 非肝细胞癌队列中利福昔明与复发性肝性脑病、自发性细菌性腹膜炎和静脉曲张出血风险降低显著相关。
  • 肝细胞癌队列中利福昔明与死亡风险无关(aHR 1.177,P=0.121)。

核心结论

  • 在无肝细胞癌的患者中,利福昔明治疗与总生存期延长及自发性细菌性腹膜炎、静脉曲张出血和复发性肝性脑病风险降低显著相关。

研究设计与样本

  • 回顾性研究纳入1042例肝性脑病患者,其中非肝细胞癌队列421例,肝细胞癌队列621例。
  • 非肝细胞癌队列中145例接受利福昔明联合乳果糖(利福昔明组),276例单用乳果糖(对照组)。
  • 肝细胞癌队列中173例接受利福昔明联合乳果糖,448例接受乳果糖。

主要发现

  • 非肝细胞癌队列多因素分析显示,利福昔明与死亡风险降低显著相关(aHR 0.697,P=0.024)。
  • 非肝细胞癌队列中利福昔明与复发性肝性脑病(aHR 0.452,P<0.001)、自发性细菌性腹膜炎(aHR 0.210,P<0.001)和静脉曲张出血(aHR 0.425,P=0.011)风险降低显著相关,但与肝肾综合征无关(aHR 0.598,P=0.08)。
  • 肝细胞癌队列中利福昔明与死亡风险无关(aHR 1.177,P=0.121),与自发性细菌性腹膜炎风险降低显著相关(aHR 0.323,P<0.001),但与静脉曲张出血(aHR 0.660,P=0.104)和复发性肝性脑病(aHR 0.689,P=0.057)无关。
  • 两组间艰难梭菌相关性腹泻风险无差异(aHR 0.028,P=0.338)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rifaximin might decrease the risk of portal hypertension-related complications by controlling small intestinal bacterial overgrowth. AIM: To evaluate whether rifaximin was associated with the risk of death and cirrhotic complications. METHODS: We conducted a retrospective study that included 1042 patients experiencing hepatic encephalopathy (HE): 421 patients without hepatocellular carcinoma (HCC; the non-HCC cohort) and 621 patients with HCC (the HCC cohort). The primary endpoint was overall survival and secondary endpoints were recurrence of HE and the development of spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS) and variceal bleeding. RESULTS: In the non-HCC cohort, 145 patients received rifaximin plus lactulose (the rifaximin group) and 276 patients received lactulose alone (the control group). The multivariate analysis revealed that rifaximin was significantly associated with lower risk of death (adjusted hazard ratio [aHR], 0.697; P = .024) and reduced the risk of recurrent HE (aHR, 0.452; P < .001), SBP (aHR, 0.210; P < .001) and variceal bleeding (aHR, 0.425; P = .011) but not HRS (aHR, 0.598; P = .08). In the HCC cohort, 173 patients received rifaximin plus lactulose and 448 patients received lactulose. Rifaximin was not associated with the risk of death (aHR, 1.177; P = .121). Rifaximin was associated with lower risk of SBP (aHR, 0.323; P < .001) but not with variceal bleeding (aHR, 0.660; P = .104) or recurrent HE (aHR, 0.689; P = .057). The risk of Clostridium difficile-associated diarrhoea was not different between the groups (aHR, 0.028; P = .338). CONCLUSIONS: In patients without HCC, rifaximin treatment was significantly associated with prolonged overall survival and reduced risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent hepatic encephalopathy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kang SH, Lee YB, Lee JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther. 2017. PMID: 28836723. doi:10.1111/apt.14275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。